CSA will use the amount to support post-market clinical studies and new indications for spray cryotherapy technology.
Intersouth Partners and First Analysis led the financing, with SV Life Sciences, Rose Park, Blue Heron Capital and other existing investors participating.
Intersouth Partners partner Rick Kent said CSA has already showed an ability to bring novel medical devices through development and into the market, as evidenced by its progress in the gastrointestinal space, and they are pleased to support their efforts to address new applications for Spray Cryotherapy.
CSA Medical CEO and president Bill Floyd said this partnership and funding will support the launch of their new platform, expanded utilization and further development of new clinical applications.
SV Life Science partner Paul LaViolette said this platform technology will address new clinical applications and they look forward to support CSA’s ongoing efforts, including the development of therapeutic treatments for the airway.
